Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase III trial of rituximab, nelarabine, Oncaspar, and palifermin within frontline therapy for adults with newly diagnosed acute lymphoblastic leukemia
ISRCTN66541317Phase 3Completed
- Sponsor
- University College London
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rituximab, pegaspargase, nelarabine and palifermin in acute lymphoblastic leukemia (ALL) (6 arms), sponsored by University College London. Primary endpoints: Event-free survival and Toxicity related to pegylated asparaginase. Started Dec 2010; status: completed.
02
Drugs
rituximabpegaspargasenelarabinepalifermin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ISRCTN66541317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN66541317.